Progress Report on the Patient Reported Outcomes Harmonization Team

Slides:



Advertisements
Similar presentations
6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Advertisements

Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.
Responding to the Patient’s Voice: the importance of Patient Reported Outcomes Dr. Kirstie Haywood Senior Research Fellow RCN Research Institute, School.
Interpreting of Patient-Reported Outcomes
Data Monitoring Models and Adaptive Designs: Some Regulatory Experiences Sue-Jane Wang, Ph.D. Associate Director for Adaptive Design and Pharmacogenomics,
1 Epoetin Alpha: FDA Overview of Patient Reported Outcome (PRO) Claims Ann Marie Trentacosti, M.D. Study Endpoints and Labeling Office of New Drugs Food.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.
…patient reported outcome (PRO) measure for your clinical study Dr Keith Meadows, DHP Research & Consultancy Ltd.
Patient Reported Outcomes in Oncology Trials Virginia Kwitkowski Clinical Reviewer-- FDA Division of Drug Oncology Products Member OND Patient Reported.
CHALLENGES FOR PRAGMATIC TRIALS IN EUROPE Donna A. Messner, PhD.
The Science of Quality By Design Janet Woodcock, M.D. May 19, 2004.
The Practical Art of Endpoint Selection: Industry Perspectives A View from the Pharma Industry of the FDA Guidance on PROs Glenn A. Phillips, Ph.D. Director.
TAP PHARMACEUTICAL PRODUCTS INC. June 2, Arthritis Drugs Advisory Committee TAP Pharmaceutical Products Inc. June 2, 2004.
Regulatory Issues in Outcomes Labeling & Advertising Louis A. Morris, Ph.D. July 17, 2001.
OLGA: A nice niche designed to meet your evolving needs Pennifer Erickson, Ph.D. Presented at the Spring meeting of the Special Library Association’s Pharmaceutical.
1 Nonprescription Drugs AC Meeting March 23, 2005 Efficacy of OTC Healthcare Antiseptics: Introduction to the Regulatory Issues Susan S. Johnson, Pharm.D.,
Evaluation Requirements for MSP and Characteristics of Designs to Estimate Impacts with Confidence Ellen Bobronnikov February 16, 2011.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
Presentation Developed for the Academy of Managed Care Pharmacy
Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development in Support of Labeling Claims Final Guidance from a Medical.
CoRPS London 26 & 27 October 2010 Center of Research on Psychology in Somatic diseases Understanding PRO in hematological disorders: Do we have a consensus?
IADSA Scientific Forum 2009 The scientific substantiation of health claims David P. Richardson Scientific Adviser to UK Council for Responsible Nutrition.
Introduction to EPARs and FDA Approval Packages: Finding and Analyzing Unpublished Information about Pivotal Studies 23 June 2008 Session Chair: Amy N.
HCA 497 MART Experience Tradition /hca497mart.com FOR MORE CLASSES VISIT
Stages of Research and Development
New Survey Questionnaire Indicators in PISA and NAEP
Design of Case Report Forms
The Master Clinician: Assessing and Teaching Clinical Competence
Quality Assurance processes
Technical Business Consultancy Project
Evaluation Requirements for MSP and Characteristics of Designs to Estimate Impacts with Confidence Ellen Bobronnikov March 23, 2011.
DATA COLLECTION METHODS IN NURSING RESEARCH
Patient Focused Drug Development An FDA Perspective
Presentation Developed for the Academy of Managed Care Pharmacy
HCS 430 MASTER Extraordinary Success/hcs430master.com
Role of The Physical Therapist in Critical Inquiry
Quality Measurement in the Value-Based Health Care Environment
Risk Communication in Medicines
FDA’s IDE Decisions and Communications
Think Family pilot WNW CDTS Adam Smith.
Presented by Rob Hemmings
Leigh E. Tenkku, PhD, MPH Department of Family and Community Medicine
Hematopoietic Cell Transplantation: Moving Beyond Survival to the Patient’s Perspective Linda J Burns, MD Medical Director, NMDP/Be The Match Health.
PSYCH 610 Competitive Success/snaptutorial.com
PSYCH 610 Education for Service/snaptutorial.com.
Crucial Statistical Caveats for Percutaneous Valve Trials
A2 unit 4 Clinical Psychology
Combination products The paradigm shift
Background to The Conference
Presentation Developed for the Academy of Managed Care Pharmacy
Communication Skills Lecture 1-2
Grampian COPD MCN Delivering Spirometry in a Community Pharmacy setting, a rural solution? Small I (1,2), Clelland J (1,2), Robertson W (1), Freeman D.
September 7, 2018 Courtney Baird, MS
IS4550 Security Policies and Implementation
Participants’ Rights Participants of clinical trials have rights, and they are protected under law when participating in clinical trials. The informed.
Friends of Cancer Research
Role of The Physical Therapist in Critical Inquiry
Standard Four Program Impact
HMS Academy Fellowship in Medical Education Research June 2, 2016
Introduction to the PRISM Framework
Research & scholarship
Regulated Health Professions Network Evaluation Framework
Pharmaceutical care planning 2 Ola Ali Nassr
Patient Involvement in the Development and Use of Safe Medicines Introductory Section – Concepts to Consider CIOMS XI WG Second Meeting October 23-24,
IMPACT OF PHARMACIST DELIVERED CARE IN THE COMMUNITY PHARMACY SETTING
Regulatory Perspective of the Use of EHRs in RCTs
Interreg-IPA Cross-border Cooperation Programme Romania-Serbia
Presentation Developed for the Academy of Managed Care Pharmacy
Aparna Raychaudhuri, Ph. D
Presentation transcript:

Progress Report on the Patient Reported Outcomes Harmonization Team Jean Paul Gagnon, PhD Aventis Pharmaceuticals Inc.

Objectives Discuss Historical Development Describe Forum Outcomes Outline Future Activities

Objectives Discuss Historical Developments

Who started the PRO Harmonization Group? European Regulatory Issues on Quality-of-Life Assessment (ERIQA) International Society of Pharmacoeconomic and Outcomes Research (ISPOR) International Society of Quality of Life (ISOQOL) Pharmaceutical Research and Manufacturers of America (PhRMA) Health Outcomes Committee (HOC)

What is its mission? To harmonize Patient Reported Outcome issues used in drug development and Evaluation.

What are its objectives? Clarify areas of concern or confusion about PRO evaluation Explain the added value of PRO outcomes among all key players, i.e., academics, regulators, industry researchers, prescribers and patients Open and maintain communication between key players Disseminate meeting outcomes, i.e., to publish papers, to participate in conferences

Objectives Discuss Historical Development Describe Forum Outcomes

Forums Three Harmonization Forums held March 31, 2000 Sept. 14, 2000 February 16, 2001 Representatives from ERIQA, ISOQOL, ISPOR, PhRMA HOC and FDA observers

March 2000 Meeting Objectives Discuss problematic issues Harmonize recommendations proposed by each organization Recommend solutions when none exist Proposed future steps to achieve consensus on problematic issues

Meeting Outcomes Consensus and areas of disagreement were identified in four areas: Concept, Study Design, Interpretation and Conditions for Claims* Group agreed to continue discussion and form a coordination group with representatives from the four organizations to organize future meeting Real issue “does outcomes research provide added value” *Report available on-line: www.mapi-research-inst/research/report.pdf

Impact of Outcomes Data Can the added-value of the outcome be demonstrated, i.e., what does the outcome provide beyond traditional measures? Does the subjective impact of treatment provide value over observer-based assessments or simple symptom scales? Does the measure capture information that is missed with traditional measures?

September 2000 Meeting Outcomes Conceptual framework was broadened to Patient Based Assessment (PBA) which was changed to Patient Reported Outcomes (PRO) for clarity Decision made to continue discussions and schedule meeting with FDA and EMEA representatives

February 2001 Meeting Objectives Clarify aspects and components of PRO evaluation Discuss where PRO can add value to clinical endpoints Suggest use of this information within labeling and promotional claims

Take Away Points Patient has a unique voice and valuable perspective that should play a role in medical decision making PROs can be measured in reliable and valid ways PROs are increasingly used as efficacy endpoints in randomized controlled trials

Patient Outcomes Assessment Sources and Examples Clinician - Reported Patient - Reported Physiological Caregiver - Reported For example, Global impressions Observation & tests of function For example, FEV1 HbA1c Tumor size For example, Dependency Functional status Global Impression Functional status Well-being Symptoms HRQL Satisfaction with TX Treatment adherence Assessment of outcome can be achieved in several ways, but most robust involves repeated application of a standardized measurement. Outcome can be defined as a change in this measurement parameter Locates outcome parameters within their primary setting. e.g. clinical or biological markers as tumor size are primarily located within the professional domain. However, parameters such as B/P may be measured by others (e.g. patients). Productivity not included as it is secondary to function

Areas of Agreement Patient Reported Outcomes (PRO) evaluation is a valid concept PRO can be operationalized PRO claims should conform with the evidence and be pre-specified PRO should be reported with fair balance in labeling and promotional claims

“Objective” “Subjective” This cartoon concludes what HRQOL stands for.. It is actually not the objective exercise test data in an hospital environment that we measure but the everyday activities at home or at work subjectively perceived by the patient himself Efficacy is often difficult to measure in disorders for which the patients subjective experience of symptoms and therapy and their impact is critical. “Objective” “Subjective” Exercise test versus physical functioning, r = 0.40 Wiklund I et al. Clin Cardiol 1991;14

Objectives Discuss Historical Development Describe Forum Outcomes Outline Future Activities

Future Plans for Pro Team Publish article on work to date, draft manuscript prepared Develop slide presentations for conferences, e.g., ISPOR, ISOQOL, DIA, others Supply content via website Continue to hold forums until deemed unnecessary Measure outcomes from Forums

February 2002 Forum Agenda Instrument development: what are the standards Instrument selection: demonstrating hypothesis, relationships to measurement Statistical issues: focus on handling missing data Interpretation: Interpreting changes that are not consistent between outcomes

Summary Discussed Historical Developments Described Meeting Outcomes Outlined Future Activities

QUESTIONS Jean Paul Gagnon jean. gagnon@aventis QUESTIONS Jean Paul Gagnon jean.gagnon@aventis.com 800-981-2491 Aventis Pharmaceuticals Inc.